LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.
Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)
Presentation: Monday, December 4, 2023 at 3:30 pm ET
Boca Raton, FL
A high-definition video webcast of the presentation will be available the following day on the Unicycive website under the Investors section: Events and Presentations.
2023 Benchmark Discovery One-on-One Investor Conference
December 7, 2023
New York, NY
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
(650) 543-5470
| Last Trade: | US$0.38 |
| Daily Change: | -0.01 -3.52 |
| Daily Volume: | 726,592 |
| Market Cap: | US$35.960M |
September 16, 2024 September 05, 2024 August 26, 2024 August 14, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
